The epigenetics of autoimmunity

Cellular and Molecular Immunology

Volumn 8, Issue 3, 2011, Pages 226-236

  Meda, Francesca ^a,b   Folci, Marco ^a   Baccarelli, Andrea ^c   Selmi, Carlo ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

DNA methylation; histone modification; microRNA; tolerance breakdown

Indexed keywords

MICRORNA;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HISTONE METHYLATION; HUMAN; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; PRIMARY BILIARY CIRRHOSIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HISTONES; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 79955675794     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2010.78     Document Type: Review

References (181)

1. Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 2008; 31: 325-330.
2. Singleton AB, Hardy J, Traynor BJ, Houlden H. Towards a complete resolution ofthe genetic architectureof disease. Trends Genet 2010; 26: 438-442.
3. Ballestar E. Epigenetics lessons from twins: prospects for autoimmunedisease. Clin Rev Allergy Immunol 2010; 39: 30-41.
4. Breton CV, Salam MT, Vora H, Gauderman WJ, Gilliland FD. Genetic variation in the glutathionesynthesispathway, airpollution, andchildren'slungfunctiongrowth. Am J Respir Crit Care Med 2010.
5. Zhang H, Zhu Z, Meadows GG. Chronic alcohol consumption decreases the percentage and number of NK cells in the peripheral lymph nodes and exacerbates B16BL6 melanoma metastasis intothe draining lymph nodes. Cell Immunol 2010.
6. Baccarelli A, Wright RO, Bollati V, Tarantini L, Litonjua AA, Suh HH et al. Rapid DNA methylation changes after exposure to traffic particles. Am J Respir Crit Care Med 2009; 179:572-578.
7. Tarantini L, Bonzini M, Apostoli P, Pegoraro V, Bollati V, Marinelli B et al. Effects of particulate matter on genomic DNA methylation content and iNOS promoter methylation. Environ Health Perspect 2009; 117: 217-222.
8. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005; 102: 10604-10609. (Pubitemid 41061601)
9. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structureof the nucleosome core particleat 2.8 A resolution. Nature 1997; 389: 251-260. (Pubitemid 27406632)
10. Arents G, Moudrianakis EN. Thehistonefold: a ubiquitousarchitectural motifutilized in DNA compaction and protein dimerization. Proc Natl Acad Sci USA 1995; 92: 11170-11174.
11. Zlatanova J, Bishop TC, Victor JM, Jackson V, van Holde K. The nucleosome family: dynamic and growing. Structure 2009; 17: 160-171.
12. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41-45. (Pubitemid 30038513)
13. Turner BM. Histone acetylation and an epigenetic code. Bioessays 2000; 22: 836-845.
14. Yoshida M, Matsuyama A, Komatsu Y, Nishino N. From discovery to the coming generationof histonedeacetylase inhibitors. Curr Med Chem 2003; 10: 2351-2358. (Pubitemid 37236392)
15. Yang XJ. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res 2004; 32: 959-976.
16. Gregory PD, Wagner K, Horz W. Histone acetylation and chromatin remodeling. Exp Cell Res 2001; 265: 195-202. (Pubitemid 32980207)
17. Kalkhoven E. CBP and p300: HATs for different occasions. Biochem Pharmacol 2004; 68: 1145-1155. (Pubitemid 39094280)
18. Roth SY, Denu JM, Allis CD. Histoneacetyl transferases. Annu Rev Biochem 2001; 70: 81-120.
19. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370: 737-749. (Pubitemid 36399066)
20. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J2007; 404: 1-13. (Pubitemid 46788079)
21. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: uniqueplayers inshapingtheepigenetic histonecode. Ann NYAcad Sci 2003;983: 84-100.
22. Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T. Methylation of histone H3 lysine 9 creates a bindingsitefor HP1 proteins. Nature 2001; 410: 116-120. (Pubitemid 32225847)
23. Bauer UM, Daujat S, Nielsen SJ, Nightingale K, Kouzarides T. Methylationatarginine 17 of histone H3 is linked to gene activation. EMBORep 2002; 3: 39-44. (Pubitemid 34144813)
24. Santos-Rosa H, Schneider R, Bannister AJ, Sherriff J, Bernstein BE, Emre NC et al. Active genes aretri-methylated at K4 of histone H3. Nature 2002; 419: 407-411.
25. Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G et al. A silenc-ing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev 2004; 18: 1251-1262. (Pubitemid 38720593)
26. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705. (Pubitemid 46273577)
27. Wysocka J, Allis CD, Coonrod S. Histone arginine methylation and its dynamic regulation. Front Biosci 2006; 11: 344-355. (Pubitemid 43253497)
28. Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT et al. Regulation of transcription bya protein methyltransferase. Science 1999; 284: 2174-2177. (Pubitemid 29297477)
29. Strahl BD, Briggs SD, Brame CJ, Caldwell JA, Koh SS, Ma H et al. Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1. Curr Biol 2001; 11: 996-1000. (Pubitemid 32589194)
30. Wang H, Huang ZQ, Xia L, Feng Q, Erdjument-Bromage H, Strahl BD et al. Methylation of histone H4 at arginine3 facilitatingtranscriptional activation by nuclear hormone receptor. Science 2001; 293: 853-857. (Pubitemid 32743973)
31. Osley MA, Fleming AB, Kao CF. Histone ubiquitylation and the regulation of transcription. Results Probl Cell Differ 2006; 41: 47-75. (Pubitemid 44856960)
32. Chen ZJ. Ubiquitin signalling inthe NF-kappaB pathway. Nat Cell Biol 2005; 7: 758-765. (Pubitemid 41079044)
33. Gardiner-Garden M, Frommer M. CpG islands invertebrategenomes. J Mol Biol 1987; 196: 261-282.
34. Illingworth RS, Bird AP. CpG islands\'a roughguide'. FEBS Lett 2009; 583: 1713-1720.
35. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21. (Pubitemid 34049633)
36. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168-174. (Pubitemid 30169152)
37. Chow J, Heard E. X inactivation andthecomplexitiesofsilencinga sexchromosome. Curr Opin Cell Biol 2009; 21: 359-366.
38. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulationbymicroRNAs: aretheanswersinsight? Nat Rev Genet 2008; 9: 102-114.
39. Ruan K, Fang X, Ouyang G. Micro RNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009; 285: 116-126.
40. Strietholt S, Maurer B, Peters MA, Pap T, Gay S. Epigenetic modifications in rheumatoid arthritis. Arthritis Res Ther 2008; 10: 219.
41. Iborra M, Bernuzzi F, Invernizzi P, Danese S. Micro RNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmun Rev 2010.
42. Sidhu SK, Minks J, Chang SC, Cotton AM, Brown CJ. X chromosome inactivation: heterogeneity of heterochromatin. Biochem Cell Biol 2008; 86: 370-379.
43. Wutz A. Xist function: bridging chromatin and stem cells. Trends Genet 2007; 23: 457-464. (Pubitemid 47259575)
44. Ozcelik T. X chromosome inactivation and female predisposition to autoimmunity. Clin Rev Allergy Immunol 2008; 34: 348-351.
45. Ezhkova E, Pasolli HA, Parker JS, Stokes N, Su IH, Hannon G et al. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 2009; 136:1122-1135.
46. Dupont C, Armant DR, Brenner CA. Epigenetics: definition, mechanismsand clinical perspective. Semin Reprod Med 2009; 27: 351-357.
47. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human diseaseand prospects for epigenetic therapy. Nature 2004; 429: 457-463. (Pubitemid 38715140)
48. Baguet A, Bix M. Chromatin landscape dynamics of the IL4-IL13 locus during T helper 1 and 2 development. Proc Natl Acad Sci USA 2004; 101: 11410-11415. (Pubitemid 39038360)
49. Mackay IR. Autoimmunity since the 1957 clonal selection theory: a little acorn to a largeoak. Immunol Cell Biol 2008; 86: 67-71.
50. Ballestar E. Epigenetics lessonsfromtwins: prospectsfor autoimmunedisease. Clin Rev Allerg Immu 2010; 39: 30-41.
51. Haque FN, Gottesman II, Wong AH. Not really identical: epigenetic differences in monozygotic twins and implications for twin studies in psychiatry. Am J Med Genet CSemin Med Genet 2009; 151C: 136-141.
52. Jarvinen P, Aho K. Twinstudies in rheumaticdiseases. Semin Arthritis Rheum 1994; 24: 19-28.
53. Clancy RM, Marion MC, Kaufman KM, Ramos PS, Adler A, Harley JB et al. Genome-wide association study of cardiac manifestations of neonatal lupus identifies candidate loci at 6p21 and 21q22. Arthritis Rheum 2010.
54. Kariuki SN, Franek BS, Kumar AA, Arrington J, Mikolaitis RA, Utset TO et al. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythe-matosus. Arthritis Res Ther 2010; 12: R151.
55. Yang W, Shen N, Ye DQ, Liu Q, Zhang Y, Qian XX et al. Genome-wideassociationstudy in Asian populations identifiesvariants in ETS1 andWDFY4associatedwithsystemic lupus erythematosus. PLoS Genet 2010; 6: e 1000841.
56. Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z et al. Genome- wideassociationstudyin a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 2009; 41: 1234-1237.
57. Cunninghame Graham DS. Genome-wide association studies in systemic lupus erythematosus: a perspective. Arthritis Res Ther 2009; 11: 119.
58. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992; 35: 311-318.
59. Korganow AS, Knapp AM, Nehme-Schuster H, Soulas-Sprauel P, Poindron V, Pasquali JL et al. Peripheral Bcellabnormalities in patientswithsystemic lupuserythematosus in quiescent phase: decreased memory B cells and membrane CD19 expression. J Autoimmun 2010; 34: 426-434.
60. Balada E, Ordi-Ros J, Vilardell-Tarres M. DNA methylation and systemic lupus erythematosus. Ann NY Acad Sci 2007; 1108: 27-136.
61. Zhou Y, Lu Q. DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients. Autoimmun Rev 2008; 7: 376-383.
62. Gorelik G, Richardson B. Aberrant T cell ERK pathway signaling and chromatin structure in lupus. Autoimmun Rev 2009; 8: 196-198.
63. Sawalha AH, Jeffries M, Webb R, Lu Q, Gorelik G, Ray D et al. Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitivegenessimilarto lupus patients. Genes Immun 2008; 9: 368-378. (Pubitemid 351791493)
64. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M et al. Evidence for impairedTcell DNAmethylation insystemic lupuserythematosusand rheumatoid arthritis. Arthritis Rheum 1990; 33: 1665-1673.
65. Oelke K, Lu Q, Richardson D, Wu A, Deng C, Hanash S et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum 2004; 50: 1850-1860. (Pubitemid 38725098)
66. Crow MK, Kirou KA. Regulation of CD40 ligand expression in systemic lupus erythematosus. Curr Opin Rheumatol 2001; 13: 361-369. (Pubitemid 32929864)
67. Lu Q, Wu A, Richardson BC. Demethylationof thesamepromoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 2005; 174: 6212-6219. (Pubitemid 40663812)
68. Lu Q, Wu A, Tesmer L, Ray D, Yousif N, Richardson B. Demethylation of CD40LG on the inactiveX in Tcellsfrom women with lupus. J Immunol 2007; 179: 6352-6358.
69. 4 T cells. J Autoimmun 2010; 35: 58-69.
70. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am 1994; 20: 61-86. (Pubitemid 24066012)
71. Batchelor JR, Welsh KI, Tinoco RM, Dollery CT, Hughes GR, Bernstein R et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex onsusceptibility. Lancet 1980; 1: 1107-1109. (Pubitemid 10100366)
72. Lee BH, Yegnasubramanian S, Lin X, Nelson WG. Procainamide isaspecific inhibitor of DNA methyltransferase 1. J Biol Chem 2005; 280: 40749-40756. (Pubitemid 41780565)
73. Deng C, Lu Q, Zhang Z, Rao T, Attwood J, Yung R et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003; 48: 746-756. (Pubitemid 36302012)
74. Mazari L, Ouarzane M, Zouali M. Subversionof B lymphocytetolerancebyhydralazine, a potential mechanism for drug-induced lupus. Proc Natl Acad Sci USA 2007; 104: 6317-6322. (Pubitemid 47186092)
75. Deng C, Kaplan MJ, Yang J, Ray D, Zhang Z, McCune WJ et al. Decreased Ras-mitogen-activated protein kinasesignalingmay cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum 2001; 44: 397-407.
76. + cells. Hum Immunol 1986; 17: 456-470. (Pubitemid 17198980)
77. Alcolado JC, Laji K, Gill-Randall R. Maternal transmission of diabetes. Diabet Med 2002; 19: 89-98. (Pubitemid 34225221)
78. Irvine DJ, Purbhoo MA, Krogsgaard M, Davis MM. Direct observation of ligand recognition byTcells. Nature 2002; 419: 845-849. (Pubitemid 35238571)
79. 4 lupus T cells. J Immunol 2004; 172:3652-3661. (Pubitemid 38337948)
80. Javierre BM, Fernandez AF, Richter J, Al-Shahrour F, Martin-Subero JI, Rodriguez-Ubreva J et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupuserythematosus. Genome Res 2010; 20: 170-179.
81. 4 T cells. J Rheumatol 2008; 35: 804-810. (Pubitemid 351747120)
82. Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y et al. Micro RNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009; 60: 1065-1075.
83. Garcia BA, Busby SA, Shabanowitz J, Hunt DF, Mishra N. Resettingtheepigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. J Proteome Res 2005; 4: 2032-2042. (Pubitemid 41814269)
84. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histonedeacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003; 111: 539-552. (Pubitemid 36228011)
85. Reilly CM, Mishra N, Miller JM, Joshi D, Ruiz P, Richon VM et al. Modulationof renal disease in MRL/lpr mice bysuberoylanilide hydroxamic acid. J Immunol 2004; 173: 4171-4178. (Pubitemid 39280783)
86. Forster N, Gallinat S, Jablonska J, Weiss S, Elsasser HP, Lutz W. p300 protein acetyltransferase activity suppresses systemic lupus erythematosus-like autoimmune disease in mice. J Immunol 2007; 178: 6941-6948. (Pubitemid 46847420)
87. Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 2009; 41: 1313-1318.
88. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010; 42: 508-514.
89. Tobon GJ, Youinou P, Saraux A. Theenvironment, geo-epidemiology, andautoimmune disease: Rheumatoid arthritis. J Autoimmun 2010; 35: 10-14.
90. Maciejewska-Rodrigues H, Karouzakis E, Strietholt S, Hemmatazad H, Neidhart M, Ospelt C et al. Epigenetics and rheumatoid arthritis: the role of SENP1 in the regulation of MMP-1 expression. J Autoimmun 2010; 35: 15-22.
91. Meinecke I, Rutkauskaite E, Gay S, Pap T. Theroleof synovial fibroblastsin mediating joint destruction in rheumatoid arthritis. Curr Pharm Des 2005; 11: 563-568. (Pubitemid 40277868)
92. Karouzakis E, Gay RE, Michel BA, Gay S, Neidhart M. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009; 60: 3613-3622.
93. Neidhart M, Rethage J, Kuchen S, Kunzler P, Crowl RM, Billingham ME et al. Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: association with genomic DNA hypomethylation and influence on gene expression. Arthritis Rheum 2000; 43: 2634-2647. (Pubitemid 32001729)
94. Nile CJ, Read RC, Akil M, Duff GW, Wilson AG. Methylationstatusof asingleCpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum 2008; 58: 2686-2693.
95. Takami N, Osawa K, Miura Y, Komai K, Taniguchi M, Shiraishi M et al. Hypermethylated promoter region of DR3, the death receptor 3 gene, in rheumatoid arthritis synovial cells. Arthritis Rheum 2006; 54: 779-787.
96. Huber LC, Brock M, Hemmatazad H, Giger OT, Moritz F, Trenkmann M et al. Histone deacetylase/acetylaseactivity intotalsynovialtissuederivedfrom rheumatoidarthritis and osteoarthritis patients. Arthritis Rheum 2007; 56: 1087-1093. (Pubitemid 46608633)
97. Grabiec AM, Tak PP, Reedquist KA. Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATson? Arthritis Res Ther 2008; 10: 226.
98. Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furumatsu T, Doi H et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum 2004; 50: 3365-3376. (Pubitemid 39372015)
99. Manabe H, Nasu Y, Komiyama T, Furumatsu T, Kitamura A, Miyazawa S et al. Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts. Inflamm Res 2008; 57: 4-10.
100. Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE et al. Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 2008; 58: 1001-1009. (Pubitemid 351564001)
101. Nakasa T, Miyaki S, Okubo A, Hashimoto M, Nishida K, Ochi M et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 2008; 58: 1284-1292. (Pubitemid 351705917)
102. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA2006; 103: 12481-12486. (Pubitemid 44267285)
103. Arora-Singh RK, Assassi S, del Junco DJ, Arnett FC, Perry M, Irfan U et al. Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis. J Autoimmun 2010; 35: 52-57.
104. Gourh P, Agarwal SK, Martin E, Divecha D, Rueda B, Bunting H et al. Association ofthe C8orf13-BLK region with systemic sclerosis in North-American and European populations. J Autoimmun 2010; 34: 155-162.
105. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974; 54: 880-889.
106. Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev 2003; 2: 181-191. (Pubitemid 36798101)
107. Wang Y, Fan PS, Kahaleh B. Association betweenenhancedtype I collagenexpression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54: 2271-2279. (Pubitemid 44051084)
108. Maxwell DB, Grotendorst CA, Grotendorst GR, LeRoy EC. Fibroblast heterogeneity in scleroderma: Clq studies. J Rheumatol 1987; 14: 756-759. (Pubitemid 17137492)
109. Czuwara-Ladykowska J, Shirasaki F, Jackers P, Watson DK, Trojanowska M. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 2001; 276: 20839-20848.
110. Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, Silver RM et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003; 163: 571-581. (Pubitemid 36909419)
111. Cross SH, Charlton JA, Nan X, Bird AP. Purification of CpG islandsusingamethylated DNA bindingcolumn. Nat Genet 1994; 6: 236-244. (Pubitemid 24188619)
112. Chiorini JA, Cihakova D, Ouellette CE, Caturegli P. Sjogrensyndrome: advances inthe pathogenesis from animal models. J Autoimmun 2009; 33: 190-196.
113. Perez P, Anaya JM, Aguilera S, Urzua U, Munroe D, Molina C et al. Gene expression and chromosomal location for susceptibility to Sjogren's syndrome. J Autoimmun 2009; 33: 99-108.
114. Alevizos I, Illei GG. Micro RNAs in Sjogren's syndrome as a prototypic autoimmune disease. Autoimmun Rev 2010; 9: 618-621.
115. Bulosan M, Pauley KM, Yo K, Chan EK, Katz J, Peck AB et al. Inflammatorycaspases arecritical for enhanced cell death in thetarget tissue of Sjogren's syndrome before diseaseonset. Immunol Cell Biol 2009; 87: 81-90.
116. Eizirik DL, Colli ML, Ortis F. Theroleof inflammation in insulitisand beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009; 5: 219-226.
117. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009; 41: 703-707.
118. Knip M, Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev 2008; 7: 550-557.
119. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G. Incidence trends for childhood type 1 diabetes in Europeduring 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373: 2027-2033.
120. Fourlanos S, Varney MD, Tait BD, Morahan G, Honeyman MC, Colman PG et al. The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyteantigengenotypes. Diabetes Care 2008; 31: 1546-1549.
121. Gillespie KM, Bain SC, Barnett AH, Bingley PJ, Christie MR, Gill GV et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 2004; 364: 1699-1700. (Pubitemid 39458146)
122. Knip M, Veijola R, Virtanen SM, Hyoty H, Vaarala O, Akerblom HK. Environmental triggers and determinants of type 1 diabetes. Diabetes 2005; 54 Suppl 2, S125-136. (Pubitemid 43348458)
123. Lefebvre DE, Powell KL, Strom A, Scott FW. Dietary proteins as environmental modifiers oftype 1 diabetes mellitus. Annu Rev Nutr 2006; 26: 175-202.
124. Kauri LM, Wang GS, Patrick C, Bareggi M, Hill DJ, Scott FW et al. Increased islet neogenesis without increased islet mass precedes autoimmune attack in diabetes-pronerats. Lab Invest 2007; 87: 1240-1251. (Pubitemid 350126710)
125. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 2008; 40: 897-903. (Pubitemid 351913645)
126. Pfleger C, Meierhoff G, Kolb H, Schloot NC. Association ofT-cell reactivitywith beta-cell function in recentonsettype 1 diabetes patients. J Autoimmun 2010; 34: 127-135.
127. Wilson CB, Rowell E, Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 2009; 9: 91-105.
128. Sawalha AH. Epigenetics and T-cell immunity. Autoimmunity 2008; 41: 245-252. (Pubitemid 351593855)
129. Aune TM, Collins PL, Chang S. Epigenetics and T helper 1 differentiation. Immunology 2009; 126: 299-305.
130. Fox JT, Stover PJ. Folate-mediated one-carbon metabolism. Vitam Horm 2008; 79: 1-44.
131. Waterland RA, Jirtle RL. Transposable elements: targets for early nutritional effectson epigenetic gene regulation. Mol Cell Biol 2003; 23: 5293-5300. (Pubitemid 36950884)
132. Lempainen J, Vaarala O, Makela M, Veijola R, Simell O, Knip M et al. Interplaybetween PTPN22 C1858T polymorphism andcow's milkformula exposure intype 1 diabetes. J Autoimmun 2009; 33: 155-164.
133. Chamson-Reig A, Arany EJ, Summers K, Hill DJ. A lowprotein diet inearly lifedelays theonsetof diabetesinthenon-obesediabetic mouse. J Endocrinol 2009; 201: 231-239.
134. Boujendar S, Arany E, Hill D, Remacle C, Reusens B. Taurinesupplementationof a low protein diet fed to rat dams normalizes the vascularization of the fetal endocrine pancreas. J Nutr 2003; 133: 2820-2825. (Pubitemid 37099765)
135. Arany E, Strutt B, Romanus P, Remacle C, Reusens B, Hill DJ. Taurinesupplement in early life altered islet morphology, decreased insulitis and delayed the onset of diabetes in non-obesediabetic mice. Diabetologia 2004; 47:1831-1837. (Pubitemid 40022420)
136. Sospedra M, Martin R. Immunology of multiplesclerosis. Annu Rev Immunol 2005; 23:683-747.
137. Akkad DA, Hoffjan S, Petrasch-Parwez E, Beygo J, Gold R, Epplen JT. Variation inthe IL7RA and IL2RA genes in German multiplesclerosis patients. J Autoimmun 2009; 32: 110-115.
138. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. Thegeneticsof multiplesclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008; 9: 516-526. (Pubitemid 351861542)
139. Brynedal B, Duvefelt K, Jonasdottir G, Roos IM, Akesson E, Palmgren J et al. HLA-A confers an HLA-DRB1 independent influenceon the risk of multiple sclerosis. PLoS One 2007; 2: e664.
140. Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallstrom E, Khademi M et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007;39: 1108-1113. (Pubitemid 47340654)
141. Zivadinov R, Uxa L, Bratina A, Bosco A, Srinivasaraghavan B, Minagar A et al. HLA-DRB1*1501,-DQB1*0301,-DQB1*0302,-DQB1*0602, and-DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. Int Rev Neurobiol 2007; 79: 521-535.
142. Chao MJ, Ramagopalan SV, Herrera BM, Lincoln MR, Dyment DA, Sadovnick AD et al. Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizestothemajorhistocompatibilitycomplex. Hum Mol Genet 2009; 18: 261-266.
143. Hansen T, Skytthe A, Stenager E, Petersen HC, Bronnum-Hansen H, Kyvik KO. Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult Scler 2005; 11: 504-510. (Pubitemid 41387692)
144. Willer CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GC. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci USA 2003; 100: 12877-12882. (Pubitemid 37339993)
145. Herrero-Herranz E, Pardo LA, Bunt G, Gold R, Stuhmer W, Linker RA. Re-expressionof adevelopmentallyrestricted potassiumchannel inautoimmunedemyelination: Kv1.4 is implicated in oligodendroglial proliferation. Am J Pathol 2007; 171: 589-598. (Pubitemid 47344691)
146. John GR, Shankar SL, Shafit-Zagardo B, Massimi A, Lee SC, Raine CS et al. Multiple sclerosis: re-expression of a developmental pathwaythat restricts oligodendrocyte maturation. Nat Med 2002; 8: 1115-1121. (Pubitemid 35175966)
147. Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD. NG2-positiveoligodendrocyte progenitorcells inadulthuman brainand multiplesclerosis lesions. J Neurosci 2000; 20:6404-6412.
148. Compston A. Limiting and repairingthe damage in multiple sclerosis. Schweiz Med Wochenschr 1993; 123: 1145-1152. (Pubitemid 23167615)
149. Mastronardi FG, Noor A, Wood DD, Paton T, Moscarello MA. Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated. J Neurosci Res 2007; 85: 2006-2016. (Pubitemid 47051489)
150. Moscarello MA, Brady GW, Fein DB, Wood DD, Cruz TF. The role of charge microheterogeneity of basic protein in the formation and maintenance of the multilayered structure of myelin: a possible role in multiple sclerosis. J Neurosci Res 1986; 15: 87-99. (Pubitemid 16173444)
151. Moscarello MA, Wood DD, Ackerley C, Boulias C. Myelin in multiple sclerosis is developmentally immature. J Clin Invest 1994; 94: 146-154. (Pubitemid 24218087)
152. Mastronardi FG, Tsui H, Winer S, Wood DD, Selvanantham T, Galligan C et al. Synergy between paclitaxel plus an exogenous methyl donor in the suppression of murine demyelinatingdiseases. Mult Scler 2007; 13: 596-609. (Pubitemid 46939525)
153. D'Souza CA, Wood DD, She YM, Moscarello MA. Autocatalytic cleavage of myelin basic protein: an alternative to molecular mimicry. Biochemistry 2005; 44: 12905-12913. (Pubitemid 41377330)
154. Musse AA, Boggs JM, Harauz G. Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope. Proc Natl Acad Sci USA 2006; 103: 4422-4427.
155. Tranquill LR, Cao L, Ling NC, Kalbacher H, Martin RM, Whitaker JN. Enhanced T cell responsiveness to citrulline-containing myelin basic protein in multiple sclerosis patients. Mult Scler 2000; 6: 220-225.
156. Baranzini SE, Mudge J, van Velkinburgh JC, Khankhanian P, Khrebtukova I, Miller NA et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 2010; 464: 1351-1356.
157. Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K et al. Transcriptionaltherapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmuneencephalomyelitis. JNeuroimmunol 2005; 164: 10-21. (Pubitemid 40826758)
158. Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin Immunopathol 2009; 31: 283-307.
159. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kD mitochondrial antigen recognized in primary biliary cirrhosis. JImmunol 1987; 138: 3525-3531. (Pubitemid 17071942)
160. Bruggraber SF, Leung PS, Amano K, Quan C, Kurth MJ, Nantz MH et al. Autoreactivity to lipoate and a conjugated form of lipoate in primary biliary cirrhosis. Gastroenterology 2003; 125: 1705-1713. (Pubitemid 37500435)
161. Nakano T, Inoue K, Hirohara J, Arita S, Higuchi K, Omata M et al. Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (a-PBC). Hepatol Res 2002; 22: 250-260. (Pubitemid 34506223)
162. Liu X, Invernizzi P, Lu Y, Kosoy R, Lu Y, Bianchi I et al. Genome-wide meta-analyses identifiesthree loci associatedwith primarybiliarycirrhosis. Nat Genet 2010; in press.
163. Invernizzi P, Selmi C, Mackay IR, Podda M, Gershwin ME. From basesto basis: linking geneticsto causation in primarybiliarycirrhosis. Clin Gastroenterol Hepatol 2005; 3: 401-410.
164. Selmi C, Invernizzi P, Miozzo M, Podda M, Gershwin ME. Primary biliary cirrhosis: doesX markthe spot? Autoimmun Rev 2004; 3: 493-499.
165. Mitchell MM, Lleo A, Zammataro L, Mayo MJ, Invernizzi P, Bach N et al. Epigenetic investigationof variablyXchromosomeinactivatedgenesin monozygoticfemaletwins discordant for primary biliary cirrhosis. Epigenetics 2011; 6
166. Invernizzi P, Miozzo M, Battezzati PM, Bianchi I, Grati FR, Simoni G et al. Frequency ofmonosomyXinwomenwith primarybiliarycirrhosis. Lancet 2004; 363: 533-535.
167. Matthias T, Shoenfeld Y. Challenges for the autoimmunologist. Clin Rev Allergy Immunol 2010; 38: 75-76.
168. Invernizzi P. Geoepidemiologyof autoimmuneliverdiseases. J Autoimmun 2010; 34: J300-J306.
169. Shapira Y, Agmon-Levin N, Shoenfeld Y. Defining and analyzinggeoepidemiology and human autoimmunity. J Autoimmun 2010; 34: J168-J177.
170. Youinou P, Pers JO, Gershwin ME, Shoenfeld Y. Geo- epidemiologyandautoimmunity. J Autoimmun 2010; 34: J163-J167.
171. van Steensel B. Mapping of genetic and epigenetic regulatory networks using microarrays. Nat Genet 2005; 37 Suppl S18-S24. (Pubitemid 40770399)
172. Cedar H, Bergman Y. Linking DNA methylation and histonemo dification: patternsand paradigms. Nat Rev Genet 2009; 10: 295-304.
173. Laird PW. Principles and challenges of genome-wide DNA methylation analysis. Nat Rev Genet 2010; 11: 191-203.
174. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet 2007; 8: 253-262. (Pubitemid 46439287)
175. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8: 286-298. (Pubitemid 46439286)
176. Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y. Epigenetics and autoimmunity. J Autoimmun 2010; 34: J207-219.
177. Cang S, Lu Q, Ma Y, Liu D. Clinical advances in hypomethylating agents targeting epigenetic pathways. Curr Cancer Drug Targets 2010; 10: 539-545.
178. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histonedeacetylase inhibitorsinclinical trials as anti-cancer agents. J Hematol Oncol 2010; 3: 5.
179. Abu-Lebdeh HS, Barazzoni R, Meek SE, Bigelow ML, Persson XM, Nair KS. Effectsof insulin deprivation and treatment on homocysteinemetabolism in people with type 1 diabetes. JClin Endocrinol Metab 2006; 91: 3344-3348. (Pubitemid 44402102)
180. Chiang EP, Wang YC, Chen WW, Tang FY. Effectsof insulinandglucoseoncellular meta-bolic fluxes in homocysteine transsulfuration, remethylation, S-adenosylmethionine synthesis, and global deoxyribonucleic acid methylation. J Clin Endocrinol Metab 2009; 94: 1017-1025.
181. Fonseca V, Dicker-Brown A, Ranganathan S, Song W, Barnard RJ, Fink L et al. Effects of a high-fat-sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism 2000; 49: 736-741. (Pubitemid 30354580)